Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death
de Andrade Mello, Paola
Savio, Luiz Eduardo Baggio
Wink, Márcia Rosângela
MetadataShow full item record
Citationde Andrade Mello, P., S. Bian, L. E. B. Savio, H. Zhang, J. Zhang, W. Junger, M. R. Wink, et al. 2017. “Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.” Oncotarget 8 (40): 67254-67268. doi:10.18632/oncotarget.18595. http://dx.doi.org/10.18632/oncotarget.18595.
AbstractExtracellular ATP (eATP) accumulation within the tumor microenvironment (TME) has the potential to activate purinergic signaling. The eATP evoked signaling effects bolster antitumor immune responses while exerting direct cytotoxicity on tumor cells and vascular endothelial cells, mediated at least in part through P2X7 receptors. Approaches to augment purinergic signaling in TME e.g. by ectonucleotidase CD39 blockade, and/or boosting P2X7 functional responses, might be used as immunomodulatory therapies in cancer treatment. In this study, we delineated the translatable strategy of hyperthermia to demonstrate impacts on P2X7 responsiveness to eATP. Hyperthermia (40°C) was noted to enhance eATP-mediated cytotoxicity on MCA38 colon cancer cells. Increased membrane fluidity induced by hyperthermia boosted P2X7 functionality, potentiating pore opening and modulating downstream AKT/PRAS40/mTOR signaling events. When combined with cisplatin or mitomycin C, hyperthermia and eATP together markedly potentiate cancer cell death. Our data indicate that clinically tolerable hyperthermia with modulated P2X7-purinergic signaling will boost efficacy of conventional cancer treatments.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34492378
- HMS Scholarly Articles